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The goal of this document is to update the original OARSI recommendations speciﬁcally for the design,
conduct, and reporting of clinical trials that target symptom or structure modiﬁcation among individuals
with knee osteoarthritis (OA).
To develop recommendations for the design, conduct, and reporting of clinical trials for knee OA we
initially drafted recommendations through an iterative process. Members of the working group included
representatives from industry and academia. After the working group members reviewed a ﬁnal draft,
they scored the appropriateness for recommendations. After the members voted we calculated the
median score among the nine members of the working group who completed the score.
The document includes 25 recommendations regarding randomization, blocking and stratiﬁcation,
blinding, enhancing accuracy of patient-reported outcomes (PRO), selecting a study population and in-
dex knee, describing interventions, patient-reported and physical performance measures, structural
outcome measures, biochemical biomarkers, and reporting recommendations.
In summary, the working group identiﬁed 25 recommendations that represent the current best
practices regarding clinical trials that target symptom or structure modiﬁcation among individuals with
knee OA. These updated recommendations incorporate novel technologies (e.g., magnetic resonance
imaging (MRI)) and strategies to address the heterogeneity of knee OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.The Task Force of the Osteoarthritis Research Society published
a set of recommendations on the design and conduct of clinical
trials in patients with osteoarthritis (OA) in 19961. The goal of thisto: J.B. Driban, Division of
Street, Box 406, Boston, MA
2.
n).
ternational. Published by Elsevier Ldocument is to update the original recommendations speciﬁcally
for the design, conduct, and reporting of clinical trials that target
symptom or structure modiﬁcation among individuals with knee
OA. This document covers general principles for all interventions,
particularly pharmacological and nutraceutical therapies, and
complements other papers in this special issue that focus on clinical
trials for surgical intervention, rehabilitation, and primary pre-
vention in OA as well as considerations regarding statistical ana-
lyses relating to these approaches.td. All rights reserved.
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reporting of clinical trials for knee OA we initially drafted recom-
mendations through an iterative process. The nine members of the
working group included representatives from industry and
academia. Initially, the working group had a series of online dis-
cussions about the content and outline for themanuscript. Next, the
members of the working group divided the writing and wrote sec-
tions of themanuscript. The sections were thenmerged into a single
document and key recommendations were extracted from each
section. Theworking group then reviewed, revised, and commented
on the complete manuscript, including the recommendations. The
working group reviewed the document twice. After the working
group members reviewed a ﬁnal draft, they scored the appropri-
ateness for 25 recommendations. Each member scored the recom-
mendations on a scale ranging from 1 to 9; in which 1 to 3 was
considered an inappropriate recommendation, 4 to 6 was consid-
ered uncertain, and 7 to 9 was an appropriate recommendation.
After themembers votedwe calculated themedian score among the
nine members of the working group. The ﬁnal document was
reviewed by a steering committee and three peer reviewers.
Trial performance
Trial design
Themost common trial design utilized in knee OA research is the
parallel two-group randomized controlled trial2, with multi-arm
parallel, crossover, withdrawal, ﬂare design, cluster and factorial
designs being the most frequent alternative designs3. Clearly, the
choice of trial design should be predicated on the nature of the
intervention and the study outcomes. For example, with symptom-
modifying drugs the choice of design is dependent on the question
asked as well as the pharmacokinetics and pharmacodynamics of
the agent to be studied. Most common are parallel-group, placebo-
and/or active-controlled trials with an initial washout of analgesic
treatment and requirement for ﬂare of pain for symptom-modifying
drugs. Cross-over studies are generally not recommended when the
intervention is anticipated to have a prolonged duration of efﬁcacy.
When other designs (e.g., withdrawal studies, adjunctive treatment
protocols) are used it is important to give reasons for the choice,
since it can affect the type of analysis and interpretation5.
It is important to determine and declare whether the trial is
evaluating superiority of one intervention over another, non-
inferiority, or equivalence, as these aspects inﬂuence the analytic
approach and the required sample size for the trial6. These issues are
addressed in more detail in a companion paper in this special issue,
which describes key analytic considerations. Furthermore, it is
important to give a detailed and pre-speciﬁed description of the in-
terventions applied in the protocol, including placebo treatment,
“usual care”, or other control and/or active interventions5. Interven-
tion duration is another critical aspect of trial design that should be
based on a combination of considerations including the biological
mechanism of action of the intervention, the natural history of the
process under studyand the responsiveness of the outcomemeasure.
Considering the complexity of designing and conducting a trial,
this document will primarily offer general guidance and recom-
mendations that a study team or sponsor should consider in its
design. For further elaboration on general design of clinical trials
the Consolidated Standards of Reporting Trials (CONSORT) provides
a comprehensive overview of the subject5.
Randomization
1. We recommend that trial methodology include effective
randomization procedures that ensure that members of thestudy team and participants remain unable to predict or inﬂu-
ence their treatment assignment. In rare situations where this is
not feasible or desirable, the deviation from this principle
should be fully described in the study report (median score ¼ 9
out of 9; minimum score ¼ 7, maximum score ¼ 9).
Randomization is the preferred method to allocate participants
into treatment groups5, since the application of non-random
methods can result in biased results7. The ideal method allocates
participants to treatment group by chance alone, i.e., the allocation
of each participant cannot be predicted5. The major advantage of
randomization is that it eliminates selection bias8, meaning that
comparisons between treatment groups will not be affected by
conscious or unconscious selection of participants with certain
characteristics to receive one treatment instead of another8. Several
methods of randomization exist5. Unless several hundred partici-
pants are in the trial, where simple randomization (all participants
have an equal probability of being in a speciﬁc group) can be
trusted to produce similar numbers9 and characteristics10 in the
groups, restricted randomization (e.g., blocked or stratiﬁed
randomization, variable block sizes) is recommended. This is of
particular importance for trials which may stop before reaching the
pre-deﬁned sample size5 or enrolling participants over a prolonged
period of time1.
The method (including type of restriction and method used for
random selection) should be speciﬁed in the protocol. It is also
important to describe the unit of randomization (e.g., patient,
clinic), the allocation ratio (the most common is equal randomi-
zation, i.e., 1:1 for two groups), and the phase of the trial for drug
trials5.
Interestingly, there are a number of pitfalls that can disclose
treatment assignment even with the use of seemingly appropriate
concealment techniques. For example, assignment codes can
sometimes be discerned in sealed envelopes when these are back-
illuminated by a bright light. In studies sequentially enrolling par-
ticipants into groups of ﬁxed sizes (e.g., class interventions), the
assignment of last enrollee is essentially disclosed if the number of
participants equals the number of randomized spots because the
last enrollee can only be assigned to one group. These pitfalls can be
minimized if the randomizer is otherwise uninvolved with conduct
of the study.
Blocking and stratiﬁcation
2. We recommend that any stratiﬁcation and/or subset analyses be
speciﬁed prior to study deployment (median score ¼ 9 out of 9;
minimum score ¼ 6, maximum score ¼ 9).
Stratiﬁcation can be used to balance speciﬁc characteristics in
each group5. A trial's credibility is weakened if the groups are not
matched for important baseline characteristics11. Stratiﬁcation can
also be used to subgroup participants within studies for secondary
endpoints of interest1. According to the recent OARSI Guidelines
for the Non-Surgical Management of Knee Osteoarthritis12, strat-
iﬁcation on the basis of subphenotypes (e.g., OA joint type (knee-
only/multiple-joint) and co-morbidities (co-morbidities yes/no))
is recommended since these factors could inﬂuence treatment
choices. Other potential characteristics to stratify for could be
high-/low-risk of OA, OA severity, age, clinic, etc5. Similarly, un-
planned subset analyses, often with small sizes, subvert the
principles of randomization, increase risk of false results, and
undermine the overall impression of methodological rigor. Strat-
iﬁcation and subgroup analyses are also addressed in a companion
paper in this special issue, which describes key analytic
considerations.
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3. We recommend adequate blinding procedures to prevent
disclosure of allocation to participants and study staff (median
score ¼ 9 out of 9; minimum score ¼ 7, maximum score ¼ 9).
4. In situations in which adequate blinding is not possible, we
recommend that an independent staff member, otherwise un-
involved with the conduct of the study (e.g., outcome data
collection) and ideally not aware of the study hypotheses,
perform the assessments or procedures that may lead to
disclosure of allocation assignment (e.g., injections or exercise
intervention; median score ¼ 9 out of 9; minimum score ¼ 7,
maximum score ¼ 9).
5. We recommend clearly indicating who was blinded and
describe the mechanisms by which this was accomplished
(median score ¼ 9 out of 9; minimum score ¼ 6, maximum
score ¼ 9).
Blinding (withholding information on the assigned interven-
tion) reduces risk of bias, especially when subjective outcomes are
assessed5,13,14. Studies with unblinded participants often have
greater attrition in the control group, more concomitant in-
terventions (e.g., rescue medication) in the control group, and
larger group differences in patient-reported outcomes (PRO) than
blinded trials15. A concern with PRO when participants are un-
blinded is that members of the active intervention group may
report greater relief while those in the reference group report less
beneﬁt or worsening.
Ideally, all participants and staff involved in running a trial should
be blinded to treatment assignment. In some situations, full blinding
may be difﬁcult or impossible. In these situations, risk of bias can be
reduced by the use of sham procedures and by making sure that
individuals assessing the study outcomes remain unaware of treat-
ment assignment. For example, trials of intra-articular interventions
whose identity can be disclosed to the injector by unique properties
such as their viscosity, often use a staff member who is otherwise
uninvolvedwith the trial to perform the arthrocentesis/injection and
prohibit communication between this individual and the study
team5. Since staff inmany roles can contribute to bias invariousways,
it is important to explicitly state who is blinded and how this was
accomplished rather than using unqualiﬁed terminology (e.g., “single
blinded” or “double blinded”)13,16,17. Appropriate reporting will help
readers determine if there was adequate blinding. For example, the
Cochrane Collaboration's tool for assessing risk of bias classiﬁes
blinding as low risk of bias, high risk of bias, or uncertain risk of bias
based on whether the blinding of key study personnel and partici-
pants was likely to inﬂuence the outcome measurements18.
Enhancing accuracy of PRO
Numerous research design features may inﬂuence the accuracy
of PRO; including, staff and participant expectations, cost or
perceived invasiveness of a treatment, washout periods, concomi-
tant pain medication use, pain reporting training, and pain inﬂa-
tion. Study teams must consider the beneﬁts and burdens of
different approaches to handling these research design features.
Furthermore, researchers should describe in their manuscripts how
they handled these key design features.
Expectations
6. We recommend training research staff about the importance of
equipoise when discussing the study interventions with the
participants (median score ¼ 8 out of 9; minimum score ¼ 7,
maximum score ¼ 9).PRO measures may be inﬂuenced by participant expectations,
which may be manipulated by direct and indirect communica-
tion19,20, methods of drug administration21,22, and color of
drugs23. Study teams should ensure that each treatment group
receives the same method of drug administration and color of
drugs. Staff expectations can also modify the placebo and treat-
ment effects via direct and indirect communication. For some PRO
staff expectations may inﬂuence the placebo effect more than the
treatment effect20. In addition to maintaining adequate blinding,
it may be beneﬁcial to train research staff about the importance of
equipoise when discussing the study interventions with the
participants.
Washout periods and concomitant pain medications
7. We recommend adopting design strategies to manage con-
founding by concomitant medications (median score ¼ 7 out of
9; minimum score ¼ 6, maximum score ¼ 9).
Concomitant or rescue pain medication may improve PRO in-
dependent of a treatment effect. There are various strategies to
deal with concomitant medication including washout periods,
recording concomitant or rescue medication use, providing a
prescription concomitant medication to every participant, and
adopting a ﬂare design24. Ideally, a study protocol would require
participants to avoid concomitant or rescue pain medication
during a clinical trial but this may have adverse inﬂuences on
study performance (e.g., increased dropouts, poor adherence with
a protocol, difﬁculty recruiting). A more stringent protocol may
maximize the treatment effect and minimize the sample size but a
study teammust be conﬁdent that they can maintain adherence to
the protocol and minimize dropouts. Conversely, a study team
may allow for concomitant or rescue pain medications emasking
the detectable treatment effect25 e but they must be able to re-
cruit a sufﬁcient sample size. If a study team decides to include
concomitant or rescue medication then they should implement a
strategy to record concomitant and rescue medication use
throughout the study. In this situation, it may be beneﬁcial for a
researcher to provide and monitor a prescription concomitant
medication and instruct the participants to avoid other concomi-
tant medications.
Outcome reporting training
8. We recommend taking steps to ensure consistency and accuracy
of outcome reporting by participants (median score¼ 8 out of 9;
minimum score ¼ 7, maximum score ¼ 9).
It is commonplace in clinical trials to verify the reliability of a
study staff member for measuring an outcome (e.g., cartilage
thickness, body weight) but we often ignore whether a participant
can reliably provide PRO measures. Individuals with ﬁbromyalgia
and neuropathic pain who have large variability in pain reports
may be more likely to respond to placebo26 but not an active
treatment27. While excluding participants who are less reliable
with PRO may make recruitment more challenging, it may be
offset by the beneﬁt of needing a smaller sample size. Alterna-
tively, it may be possible to train participants to become more
reliable with PRO measures but this remains an active area of
research. Finally, researchers should be aware of the risk of pain
inﬂation, particularly if study eligibility criteria include a minimal
pain threshold. One remedy to this may be to analyze baseline
pain and/or requiring a prespeciﬁed pattern, duration and
magnitude of pain measured after a screening visit with this in-
formation withheld from the potential participant and even the
site investigator.
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Selecting a study population
The study population should be deﬁned by speciﬁc inclusion
and exclusion criteria. Depending on the study objectives and the
stage of a study, these criteria may need to be very stringent to
ensure a homogenous study population, or can be broad to ensure a
more heterogeneous population. Broad patient eligibility allows for
generalizable application of positive results; however, because of
the larger degree of population heterogeneity, positive results for a
responsive subpopulation may be masked. If subpopulations can be
deﬁned or hypothesized, prospective stratiﬁcation of the study
population should be considered.
An efﬁcacy trial should typically study a fairly homogeneous
population having a single target joint site affected by OA. If the
population also includes individuals with OA at joint sites other
than the index knee, the sample size should ideally be increased to
permit stratiﬁed analyses of the subsets of individuals according to
OA localization joints (e.g., knee and hip) with adequate statistical
power. This may be particularly important since PRO responses
may differ among individuals with unilateral knee OA, bilateral
knee OA28,29, OA at other joints (e.g., hip or spine), or generalized
OA. These analyses, however, can become complicated when some
individuals have involvement at multiple joint regions.
Amajor goal of proof of concept or early exploratory studies is to
enroll a well-deﬁned, homogeneous population in whom the
intervention is considered most likely to be efﬁcacious, not tomake
conclusions that can be generalized1,30,31. A rationale for inclusion
or exclusion of certain study candidates should be described in the
protocol. Patient selection may also need to consider mechanism of
action of the study treatment, pharmacokinetic parameters, drug-
food and/or drugedrug interactions, etc. The exclusion criteria
also need to consider patient safety protection. For example, risks
to the fetus of pregnant women or women of childbearing potential
should be carefully considered, and if needed special criteria pro-
posed (e.g., excluding pregnant women from the trial)1.
Study population characteristics that should be considered for
generalizability are not dissimilar from recent recommendations by
others31e33 and include, but are not limited to, demographic fea-
tures (e.g., age, sex, race), diagnosis (including etiology of the OA,
e.g., idiopathic or post-traumatic), duration of OA symptoms, OA
symptom intensity, speciﬁc OA signs/symptoms/deformities, struc-
tural features (e.g., joint space narrowing, bone marrow lesions),
medical comorbidities, concomitant medications and/or therapies,
and socioeconomic, psychosocial and/or quality of life factors.Comorbidities
9. We recommend that the study design should be explicit about
inclusion or exclusion of comorbidities (median score ¼ 9 out of
9; minimum score ¼ 6, maximum score ¼ 9).
Comorbidities may complicate the symptoms and/or structures
in knee OA. For example, a signiﬁcant percentage of patients with
knee OA have one or more comorbidities that may complicate knee
sensation, such as, concomitant neurological conditions (e.g.,
sciatica, diabetic neuropathy, multiple sclerosis), hip or back pain or
other chronic pain conditions34e36. Psychological status (e.g., anx-
iety, depression, poor sleep quality, pain catastrophizing) may
affect patient assessments37,38. Some comorbidities (e.g., back pain,
fatigue, symptom counts and depression) have been reported to
signiﬁcantly increase WOMAC scores for knee OA39.
In addition to factors affectingperceptionof knee symptoms, other
factors, such as weight (e.g., obesity), level of physical activity, varus/valgusdeformityorprior surgical intervention(e.g.,meniscectomy)of
the study knee, may affect the structural progression of knee OA and
further contribute to heterogeneity in a study population30.
10. We recommend planning a priori for recruiting or analyzing
subphenotypes (median score ¼ 7 out of 9; minimum
score ¼ 6, maximum score ¼ 9)Origin of OA disorder
At the study knee level, heterogeneity also exists. Knee-speciﬁc
phenotypes may need to be considered. For example, OA may be a
common manifestation of different diseases with various triggers
(e.g., mechanical, genetic). Study populations should be as ho-
mogenous as possible with regard to the underlying etiology. When
a study team recruits participants based on a speciﬁc etiology this
should be speciﬁed and should be the same in all patients (e.g.,
malaligned knee, anterior cruciate ligament injury, primary
compartment of the knee affected (patellofemoral vs medial
tibiofemoral vs lateral tibiofemoral)). It is suggested that in studies
of patients with OA without a clear etiology, exclusions for sec-
ondary OA of the study joint should be considered (e.g., exclude
septic arthritis, inﬂammatory joint disease, gout, articular fracture,
major dysplasias or congenital abnormality, hemochromatosis)1.
11. We recommend characterizing at baseline the severity of the
disease, the pathological subphenotype (e.g., synovitic, bone
marrow lesion, meniscal), structural subphenotype (e.g.,
knee compartment), and pain subphenotype (e.g., neuro-
pathic, nociceptive; median score ¼ 7 out of 9; minimum
score ¼ 6, maximum score ¼ 9)
Characterizing pathological and structural subphenotypes
The radiographic severity of OA in each patient should be
quantiﬁed and documented using aggregate radiographic criteria
(e.g., Kellgren and Lawrence scale). The range of grades used for
entry criteria among treatment and placebo (or control) groups
should be comparable and similar. These radiographic entry criteria
should also be appropriate for the speciﬁc study design. For
example, a cohort that included advanced severity might be
appropriate in studies of a symptom-modifying drug while a cohort
limited to minimal severity would be more appropriate for studies
of a structure-modifying drug intended to retard progression1.
Furthermore, for pragmatic trials it may be reasonable to forego
radiographic assessments of disease severity and focus on clinical
diagnoses of knee OA.
Magnetic resonance imaging (MRI) has the potential for evalu-
ation of OA due to its ability to evaluate the morphology of all
structures of the joint, as well as surrounding soft tissues. Re-
searchers should consider the relevance of speciﬁc pathological
subphenotypes. This may include recruiting participants with
speciﬁc pathological ﬁndings (e.g., bone marrow lesions [BMLs],
synovitis) or planning to stratify participants based on the presence
or size of these ﬁndings. For example, a study team may recruit
participants with BMLs if they will be administering an interven-
tion that targets bone turnover.
OA pain subphenotypes
Regardless of the origin of OA disorder to be studied, for
symptomatic drug trials, pain subphenotype should be considered.
OA has been described as a chronic mild to moderate nociceptive
(non-neuropathic) pain condition40,41. Accumulating evidence from
animal and humans has found that neuropathic pain components
exist in knee OA pain, with evidence of peripheral and central nerve
sensitization42, as well as nerve ending damage and regrowth43,44.
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patients ranges from 19% to 29% when potential confounding
comorbidities are excluded35,36. Due to mechanism of action,
pharmacokinetics and method of delivery, some therapeutics may
be selectively effective in nociceptive pain or neuropathic pain
rather than the entire OA cohort45e47, though this has yet to be
demonstrated. Speciﬁc study criteria to ensure homogenous study
population by pain type, or application of stratiﬁcation of partici-
pants with different pain subphenotypes, should be considered in
interventional OA trials with the goal of targeting the unique
characteristics of speciﬁc pain therapies to individual needs30,48.
Diagnostic tools have been developed and validated to charac-
terizenociceptivepain, neuropathicpainoramixtureof both. Someof
these tools are patient administered questionnaires, such as, pain-
DETECT49, modiﬁed painDETECT for knee OA36, self-report Leeds
assessment of neuropathic symptoms and signs (S-LANSS)50, neuro-
pathic pain symptom inventory (NPSI)51, andDouleurNeuropathique
en 4 Questions (DN4-Interview52). Some tools are combinations of
interview questions with simple sensory examinations such as the
DN452, LANSS, and the standardized evaluation of pain (StEP)53.
Pain intensity assessment may also be used to subphenotype
patients. Classically, pain intensity can be simply uni-dimensionally
measured by numeric rating scale (NRS) or visual analog scale (VAS)
associated with physical function or not. However, pain is an un-
pleasant sensory and emotional experience. Hence, a multi-
dimensional pain assessment tool may more comprehensively
evaluate pain status and characterize patients responsive to in-
terventions. For example, the intermittent and constant osteoar-
thritis pain (ICOAP)measure evaluates pain intensity, frequency, and
impact onmood, sleep, and quality of life, independent of pain effect
on physical function (see Table I)54. For many multi-dimensional
assessment tools, the minimally clinically important differences in
total score or subscale scores remain to be established. Hence, in-
vestigators may need to plan strategies to determine minimally
clinically important differences for these scores in their studydesign.
Selecting an index knee
12. In studies that require selection of an index knee we
recommend deﬁning a selection strategy in advance (median
score ¼ 9 out of 9; minimum score ¼ 7, maximum score¼ 9).Symptom modifying interventions
13. We recommend selecting symptomatic cut-points that may
avoid ceiling or ﬂoor effects and permit analysis of the
minimally clinically important differences (median score ¼ 8
out of 9; minimum score ¼ 6, maximum score ¼ 9).
In situations where it is appropriate to select a single joint, a
decision algorithm should be deﬁned in the study protocol. For
example, it is common in symptom-modifying trials to select one
knee based on symptom severity. However, simultaneous assess-
ment of the other OA knee or other OA joints is theoretically
possible using appropriate statistical methodology.
In general for studies of symptomatic response, the level of
symptoms at baseline should be of sufﬁcient severity to permit
detection of change, i.e., avoid ﬂoor effects. For example, after
washout, when the participants avoid taking analgesic medication,
inclusion criteria for symptomatic response could include the
following:
 Pain intensity: e.g., numerical rating scale (0e10, where 0 is no
pain and 10 is extreme pain) 4.0 and 9.032,33. For studies ofacute symptom modifying drugs, the study knee symptoms
should be at least moderate to severe30 (e.g., pain of at least
40 mm as measured on the 100-mm VAS).
Structure-modifying interventions
14. We recommend selecting structural severity cut-points that
may avoid ceiling and ﬂoor effects and permit analysis of the
minimally clinically important difference (median score ¼ 8
out of 9; minimum score ¼ 6, maximum score ¼ 9).
For studies of structure-modifying interventions, if the study
team selects an index knee then the decision algorithm should be
deﬁned a priori. For example, one may select the knee with greater
disease severity. Special subpopulations of participants who are at
high risk for development of OA or have amore rapid progression of
their OA may be advantageous (e.g., malalignment, obese women
with unilateral radiographical OA or patients who have undergone
meniscectomy). Speciﬁc patient populations should be clearly
deﬁned. In addition, the following should be considered1:
 Kellgren and Lawrence radiographic entry criteria: prevention
studies: grades 0 or 1 (i.e., absence of a deﬁnite osteophyte);
disease retardation/reversal studies: grades 2 or 3 (i.e., sufﬁcient
remaining inter-bone distance to permit detection of wors-
ening/progression) or a certain pre-deﬁned amount of joint
space width (in mm).
Trial performance: interventions
15. We recommend describing interventions (active and pla-
cebo) in sufﬁcient detail to allow others to replicate an
intervention (median score ¼ 9 out of 9; minimum score ¼ 7,
maximum score ¼ 9).
It is critical for study teams to describe interventions, including
control interventions, in sufﬁcient detail to permit clinicians and
other study teams to replicate an intervention55. The CONSORT
statement outlines important aspects of different types of in-
terventions that should be reported55. Key elements may include
dose (e.g., drug dose, duration of exercise session), method of
administration (e.g., oral or intravenous, clinician supervised or
home exercise program), and frequency and duration of adminis-
tration55. Study teams should also describe if the interventions
followa ﬁxed regimen or could be adapted based on the response of
each individual. The criteria that may warrant the participant to
stop receiving an intervention should also be documented55. If the
control group receives “usual care” then the study team should
describe how this was deﬁned and monitored55. Sufﬁcient report-
ing may be challenging for non-pharmacological interventions
because the study team will need to describe how interventions
were standardized, the expertise of the individual(s) administering
the treatment protocol, and how the study team insured that in-
dividuals administering the protocol adhered to the protocol. For
more complex non-pharmacological interventions it may be ad-
vantageous to develop videos or illustrated documents that can
facilitate replicating the interventions. For pharmacological and
nutraceutical trials study teams should describe quality control
steps and how they veriﬁed bioavailability (e.g., measuring serum
vitamin D levels in a clinical trial with Vitamin D56).
Trial performance: outcome measures
16. We recommend that trials should use patient-reported and
objective outcome measures that are valid, reliable, and
Table I
Commonly used PRO measures in knee OA trials that address pain, physical function, & patient global assessment
Instrument Disease-speciﬁc Methods Domains Number of items; recall period;
time to complete
Interpretation of score Access to instrument and
additional information
Western Ontario and McMaster
Universities osteoarthritis
index (WOMAC)
Yes Self-administered (5-point
Likert, 11-point NRS, or
100 mm VAS)
Pain
Stiffness
Physical Function
24 items; previous 48 h;
5e10 min
3 subscales; Likert version: pain
(0e20), stiffness (0e8),
function (0e68) with higher
scores indicating more
problems.
http://www.womac.com/
Available in several languages
by licensing fee
Knee Injury and Osteoarthritis
Outcome Score (KOOS)
Yes Self-administered (5-point
Likert)
Pain
Other Symptoms
Function in Daily Living
Function in Sport and
Recreation
Quality of Life
42 items; previous week;
10 min
5 subscales; 0e100 with a
higher score indicating no
problems
http://www.koos.nu/
Freely available in several
languages
The Measure of Intermittent
and Constant Osteoarthritis
Pain (ICOAP)
Yes Self or interviewer
administered (5-point
Likert)
Constant Pain
Intermittent Pain
11 items; previous week;
<10 min
2 subscales; Constant pain (0
e20), Intermittent pain (0e24).
Higher score indicates worse
pain.
http://www.oarsi.org/research/
outcome-measures#question
naire
Freely available in 10 languages
Short Form 36 (or 12) No Self or interviewer
administered
Physical and Mental Health
(based on an 8 dimensions)
36 (or 12) items; 1-week and
4-week recall versions;
5e10 min
8 subscales; 0e100 with a
higher score indicating a better
health
http://www.sf-36.org/
Available in several languages
by licensing fee
Patient Reported Outcomes
Measurement Information
System (PROMIS)
No Self-administered (with
computer adaptive versions
available)
Covers several different
domains related to physical,
mental, and social health
Varies depending on the
speciﬁc instrument
Varies depending on the
speciﬁc instrument, however
all instruments use a T-score
(¼mean of 50 and SD of 10)
with higher score meaning
more of a domain
http://www.nihpromis.org/
Available in English, Spanish
and some in other languages by
submitting a registration form
The Full Health Assessment
Questionnaire (HAQ)
No Self-administered Disability
Discomfort
Drug toxicity
Health Care Utilization and Cost
Supplemental items
(demographics, lifestyle, and
health behaviors)
22 items þ other questions;
Previous week/4 weeks/6
months (varies within
instrument); 20e30 min
0e3, with 3 being worst
functioning; Pain (0e100) and
global health (0e100) with 100
being severe pain and very poor
health
http://aramis.stanford.edu/
HAQ.html
Freely available in English,
other translations may exist
The Improved HAQ (formerly
HAQ-DI)
No Self-administered Functional Ability
Pain
Global Health
22 items; no recall period/
previous week; ~5 min
0e100, with 100 being worst
functioning; Pain (0e100) and
global health (0e100) with 100
being severe pain and very poor
health
http://aramis.stanford.edu/
HAQ.html
Freely available in English,
other translations may exist
EQ-5D No Self-administered (3 or 5
response categories and a
VAS item)
General Health
Mobility
Self-care
Usual Activities
Pain/Discomfort
Anxiety/Depression
6 items; today; <5 min 3/5 (depending on version)
health states transferable to a
Index from 0 to 1 with 1
representing full health; VAS
item (0e100) with 100 being
best imaginable health
http://www.euroqol.org/
Available in several languages
by submitting registration form
(in some cases a fee applies)
T.E.M
cA
lindon
et
al./
O
steoarthritis
and
Cartilage
23
(2015)
747
e
760
752
T.E. McAlindon et al. / Osteoarthritis and Cartilage 23 (2015) 747e760 753responsive to change (median score ¼ 9 out of 9; minimum
score ¼ 6, maximum score ¼ 9).
17. We recommend that primary and secondary outcome mea-
sures should be deﬁned a priori and indicated when regis-
tering a trial (median score ¼ 9 out of 9; minimum score ¼ 7,
maximum score ¼ 9).PRO measures
Any outcome evaluated directly by the patient and based on the
patient's perception of a disease and its treatment(s) is called a
patient-reported outcome (PRO). PRO measures allow patients to
report how they feel, function and how their quality of life is
impacted directly, without interpretation from healthcare profes-
sional or others57. PROmeasures are away of recording how people
rate their own health status and provide patient level data to allow
quality improvement across health services. These outcomes
measures are particularly common for treatments developed to
treat conditions where intentions are to ameliorate symptoms,
facilitate functioning and improve quality of life. PRO data can be
used to measure the beneﬁt and risk of a treatment (e.g., side ef-
fects, inconvenience). The scope of PRO can vary from single
concept with either single (e.g., pain intensity) or multiple items
(e.g., Health Assessment Questionnaire e HAQ) to multi-concept,
multi-item patient-assessed measure, all the way to certain com-
plex multidimensional measures (e.g., SF-36 to measure Health-
Related Quality of Life e HRQL). Instruments used to measure
outcome in clinical.
Instruments used to measure PROs in clinical trials of knee OA
should be valid, reliable and responsive to change. PROs have a role
in product labeling to allow communication of treatment beneﬁts
important from the patient's perspective to physician, payers and
others. The FDA PRO guidance58 provides details on the types of
evidence and documentation required for any PROmeasure used to
support regulatory approval or label claims in US. If needed, a new
instrument can be developed. In some situations, the new instru-
ment can be developed by modifying an existing instrument
following regulatory guidelines59. However, precautions should be
taken when developing or modifying instruments since this can
affect the psychometric properties of the instrument.
18. We recommend for assessing symptomatic outcomes using
the three core clinical measures: pain, physical function, and
patient global assessment (median score ¼ 9 out of 9; min-
imum score ¼ 6, maximum score ¼ 9).The core set of PRO measures in knee OA trials
A core set of three clinical measures was speciﬁed in the
Outcome Measures in Rheumatology Clinical Trials (OMERACT) III
Conference60 and ratiﬁed by the 1996 OARSI Task Force OA Clinical
Trials Guidelines1: pain, physical function and patient global
assessment. See Table I for a list of PROs that are commonly used in
knee OA clinical trials to address these three measures.
Pain
The degree of joint pain in the index joint(s) should be graded.
Pain can be recorded on a ﬁve-point Likert scale (e.g., none, mild,
moderate, severe, very severe), 11 point (0e10) NRS-, or on a
100 mm VAS. Single questions about pain can be used but the ac-
tivity causing pain could be informative: e.g., weight bearing pain,
resting pain, night pain, walking pain, pain after activity, and pain
after stair climbing. If using a single question, it is important to
consider the type of activity and timing of pain that may be mostpertinent to the study population. For example, pain after running
may bemore important to young physically active populations with
early-onset knee OA after injuries while pain with walking may be
more relevant to older participants who are less active. This also
raises the question if it would be ideal to assess a participant's
recent physical activity and pain to better discriminate who is
having pain while sedentary vs those who have pain but continue
to lead active lives61.
Pain measurements as part of instruments with multi-item (e.g.,
HAQ)62e64, multi-concept (e.g., WOMAC pain subscale)65 or
multidimensional measures can be used as well. Many of the pain
questions or instruments deﬁne a speciﬁed recall period. The form
of pain (whether constant or intermittent) may also be distin-
guished and documented using the ICOAP instrument54. Pain can
also be assessed after speciﬁc activities (e.g., a walk test). If a pain
assessment occurs after an activity then the study team should
ensure consistency throughout the trial with the type and duration
of activity as well as the timing of the pain assessment after the
activity.
Physical function
Physical function/disability is usually measured on a rating scale
(Likert, NRS or VAS). Many multidimensional instruments have a
physical function subscale, such as the WOMAC physical function
subscale65, KOOS function subscale66,67 and the Health assessment
questionnaire disability index (HAQ-DI/Improved HAQ)62e64. Pa-
tient Reported Outcomes Measurement Information System
(PROMIS) has multiple physical function instruments that can be
used to evaluate the physical function of knee OA68. For a more
thorough description of some of the self-reportedmeasures of knee
function see Collins et al. 201169 and Table I.
Patient global assessment
The patient's assessment of his/her global status is usually
measured on a rating scale (Likert, NRS or VAS). There is currently
no validated standard question, and no standard response format
for conducting thismeasure. A commonly used standard question is
“Considering all the ways your knee OA affects you, how have you
been during the past (time frame)?”.
Health-related quality of life measures
Measurement, at appropriate intervals, of health-related quality
of life and utility is also recommended, although these are not
currently part of the core set of outcome measures. They not only
allow measurement of the patient's quality of life or the utility of
their health status, but also facilitate economic analyses of health
care and cross-disease comparisons of outcome. Examples of
health-related quality of life instruments include the SF-3670,71,
Sickness Impact Proﬁle (SIP)72, and EQ-5D73,74. Utility can be
measured using the EQ-5D or The Health Utilities Index (HUI)75,76.
Objective outcome measures (e.g., physical function)
19. We recommend using a set of physical performance mea-
sures for knee OA (median score ¼ 6 out of 9; minimum
score ¼ 4, maximum score ¼ 9).
An essential requirement of all objective measures is that they
are valid and reproducible with reasonable intra- and intertester
reliability77e79. Kerlinger has described objective measurements in
terms of reliability/agreement, “An objective procedure is one in
which agreement among observers is at maximum. In variance
terms, observer variance is at a minimum.”80 In clinical research
and clinical practice, performance-based tests are commonly used
as objective outcome measures to assess physical function.
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of physical function represents the tests of typical activities rele-
vant to individuals diagnosed with hip or knee OA, including those
following joint replacements (i.e., 30 s chair stand test, 40 m fast-
paced walk test, stair climb test, the timed up and go test, and
6 min walk test). These tests are complementary to patient-
reported measures and are recommended as prospective
outcome measures in OA research and to assist decision-making in
clinical practice81. The recommended set comprises three core tests
and two additional tests. They are intended for use by both clini-
cians and researchers as performance outcome measures and are
viewed as complementary to established PROs. While these tests
may be ideal for most study populations it is important to recognize
that some populations may requiremore challenging performance-
based tests. For example, young, physically active participants with
early-stage knee OA after an injury may require more challenging
performance-based tests (e.g., single-legged hop tests)82.
Structural outcome measures
20. We recommend radiography or MRI for demonstration of
structure modiﬁcation. The choice of imaging technique and
outcome measures (primary and secondary) should be
predicated on the expected mechanism of the intervention
(e.g., bone marrow lesions for bone therapies, synovitis/
effusion volume for anti-inﬂammatory agents; median
score¼ 8 out of 9; minimum score¼ 7, maximum score ¼ 9).
21. We recommend assessing reliability and other metrics of
measurement error and sensitivity, including scan-rescan
reproducibility at each study site (median score ¼ 8 out of
9; minimum score ¼ 6, maximum score ¼ 9).
22. We recommend that disease modiﬁcation be deﬁned as an
improvement in OA-related symptoms (e.g., joint pain) and
one of the following structural outcomes:
a. Reduction or reversal of joint space narrowing (contin-
uous outcome)
b. Reducing the progression of cartilage damage or reversal
of cartilage damage on MRI (e.g., thickness, denudation;
median score¼ 7 out of 9; minimum score¼ 6, maximum
score ¼ 9).Measurement of joint spacewidth on X-ray radiograph has been
the best accepted endpoint for detecting disease modiﬁcation83;
however, it is insensitive, susceptible to measurement error, and
does not directly image the tissues of interest. MRI has potential
because it can image speciﬁc tissues but it is more expensive. MRI is
valid, reproducible, and could also provide sensitive detection of
response to intervention and help clarify the processes inﬂuenced
by the therapy84. For further details on matters relating to acqui-
sition methods/techniques (including guidance on positioning for
radiography, sequence/protocol recommendations/hardware for
MRI); commonly encountered problems (including positioning,
hardware and coil failures, sequences artifacts); quality assurance/
control procedures; measurement methods; measurement perfor-
mance (reliability, responsiveness, validity); recommendations for
trials; and research recommendations see the accompanying
manuscript on knee OA imaging in this issue.
Some studies may also use a total knee replacement as an end-
point since it is a clinically relevant end-point that is inﬂuenced by
symptomatic and structural severity. However, these studies will
require a large sample size because the annual incidence rates of
total knee replacements among individuals with end-stage OA is
low (1.6e11.9%)85. Another important limitation to using a total
knee replacement as an end-point is that it could be inﬂuenced by
extraneous variables; such as, age, sex, race, comorbidities,geographic region, insurance coverage, and patient's educational
level86e88. To circumvent the concerns noted above some in-
vestigators have tried to develop criteria to deﬁne appropriateness
for total knee replacement or a virtual total knee replacement89.
While these criteria are promising they should be used with
caution since they require further validation.Biochemical biomarkers
23. We recommend collecting and storing biological ﬂuids to
assess the metabolic effect of a treatment on joint tissues
(median score ¼ 7 out of 9; minimum score ¼ 5, maximum
score ¼ 9).
The National Institutes of Health (NIH) deﬁnes a biomarker as “a
characteristic that is objectively measured and evaluated as an in-
dicator of normal biologic processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention”. Based on
their characteristics, biomarkers can be divided in two major
groups: the so-called “soluble” or “wet” biomarkers, usually
measured in body ﬂuids such as serum, plasma, urine or synovial
ﬂuid and usually reﬂecting variation of an endogenous substance
(proteins, protein fragments, metabolites, carbohydrate or genomic
biomarkers (RNA or DNA)) in these ﬂuids; and the so-called “dry”
biomarkers consisting of VAS, questionnaires, quantitative sensory
testing, physical tests or imaging features. Ideally, soluble bio-
markers should be speciﬁc of one single joint tissue and/or one
particular pathogenic process and should reﬂect metabolic changes
occurring in this particular tissue90. Theoretically, these existing
biomarkers can be categorized according to the OA process targeted
in markers of cartilage degradation/synthesis, bone remodeling,
synovial tissue degradation/activity. In 2006 Bauer et al. proposed
the “BIPED” soluble biomarker classiﬁcation in which the acronym
“BIPED” stands for Burden of disease, Investigative, Prognostic, Ef-
ﬁcacy of Intervention and Diagnostic91. More recently, the OARSI/
FDA osteoarthritis Biomarkers Working Group adopted the classi-
ﬁcation system of Wagner92 to classify biomarkers into four cate-
gories (exploration, demonstration, characterization and surrogacy
levels) according to their current level of qualiﬁcation for drug
development93. To qualify for the efﬁcacy of intervention category,
a marker must demonstrate a statistically signiﬁcant relationship
between treatment-related changes in a biomarker and the clinical
or imaging outcome. Speciﬁcity of a biomarker or a cluster of bio-
markers for one particular tissue, one particular joint and/or one
particular pathogenic process are key elements for the interpreta-
tion of soluble marker value.
Currently, no biomarker is considered a surrogate measures for
clinical outcomes in OA and cannot be used as the basis for regu-
latory decisions in OA drug development93. However, we encourage
collection of biological ﬂuids in randomized clinical trials to
investigate the metabolic effect of a treatment on joint tissue and to
qualify a biomarker or a cluster of biomarkers for treatment
development and use in the context of a personalized approach of
OA management. For further details on matters relating to bio-
markers see the accompanying manuscript in this issue.Reporting recommendations
24. We recommend registering a clinical trial in the appropriate
registry prior to enrolling participants (e.g., Clinicaltrials.gov;
median score ¼ 9 out of 9; minimum score ¼ 7, maximum
score ¼ 9).
25. We recommend that clinical trial methodology and results be
reported in a format that allows for their inclusion in pooled
Table II
CONSORT checklist and summary of OARSI knee clinical trial consensus statement recommendations
Section/Topic CONSORT
item number
CONSORT checklist item OARSI knee clinical trial consensus recommendation
Title and abstract
1a Identiﬁcation as a randomised trial in the title
1b Structured summary of trial design, methods, results, and
conclusions
Introduction
Background and
objectives
2a Scientiﬁc background and explanation of rationale
2b Speciﬁc objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial)
including allocation ratio
7. We recommend adopting design strategies to manage
confounding by concomitant medications.
3b Important changes to methods after trial commencement
(such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants 9. We recommend that the study design should be explicit
about inclusion or exclusion of comorbidities.
10. We recommend planning a priori for recruiting or
analyzing subphenotypes.
11. We recommend characterizing at baseline the severity
of the disease, the pathological subphenotype (e.g.,
synovitic, bone marrow lesion, meniscal), structural
subphenotype (e.g., knee compartment), and pain
subphenotype (e.g., neuropathic, nociceptive).
12. In studies that require selection of an index knee we
recommend deﬁning a selection strategy in advance.
13. We recommend selecting symptomatic cut-points that
may avoid ceiling or ﬂoor effects and permit analysis of the
minimally clinically important difference.
14. We recommend selecting structural severity cut-points
that may avoid ceiling and ﬂoor effects and permit analysis
of the minimally clinically important difference.
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufﬁcient details to
allow replication, including how and when they were
actually administered
6. We recommend training research staff about the
importance of equipoise when discussing the study
interventions with the participants.
15. We recommend describing interventions (active and
placebo) in sufﬁcient detail to allow others to replicate an
intervention
Outcomes 6a Completely deﬁned pre-speciﬁed primary and secondary
outcome measures, including how and when they were
assessed
8. We recommend taking steps to ensure consistency and
accuracy of outcome reporting by participants.
16. We recommend that trials should use patient-reported
and objective outcomemeasures that are valid, reliable, and
responsive to change.
17. We recommend that primary and secondary outcome
measures should be deﬁned a priori and indicated when
registering a trial.
18. We recommend for assessing symptomatic outcomes
using the three core clinical measures: pain, physical
function, and patient global assessment.
19. We recommend using a set of physical performance
measures for knee OA.
20. We recommend radiography or MRI for demonstration
of structure modiﬁcation. The choice of imaging technique
and outcome measures (primary and secondary) should be
predicated on the expected mechanism of the intervention
(e.g., bone marrow lesions for bone therapies, synovitis/
effusion volume for anti-inﬂammatory agents).
21. We recommend assessing reliability and other metrics
of measurement error and sensitivity, including scan-rescan
reproducibility at each study site.
22. We recommend that disease modiﬁcation be deﬁned as
an improvement in OA-related symptoms (e.g., joint pain)
and one of the following structural outcomes:
a. Reduction or reversal of joint space narrowing
(continuous outcome)
b. Reducing the progression of cartilage damage or reversal
of cartilage damage on MRI (e.g., thickness, denudation).
23. We recommend collecting and storing biological ﬂuids
to assess the metabolic effect of a treatment on joint tissues.
6b Any changes to trial outcomes after the trial commenced,
with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and
stopping guidelines
(continued on next page)
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Table II (continued )
Section/Topic CONSORT
item number
CONSORT checklist item OARSI knee clinical trial consensus recommendation
Randomisation: 1. We recommend that trial methodology include effective
randomization procedures that ensure that members of the
study team and participants remain unable to predict or
inﬂuence their treatment assignment. In rare situations
where this is not feasible or desirable, the deviation from
this principle should be fully described in the study report.
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as
blocking and block size)
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation
sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence until
interventions were assigned
Implementation 10 Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to
interventions
Blinding 11a If done, who was blinded after assignment to interventions
(for example, participants, care providers, those assessing
outcomes) and how
3. We recommend adequate blinding procedures to prevent
disclosure of allocation to participants and study staff.
4. In situations in which adequate blinding is not possible,
we recommend that an independent staff member,
otherwise uninvolved with the conduct of the study (e.g.,
outcome data collection) and ideally not aware of the study
hypotheses, perform the assessments or procedures that
may lead to disclosure of allocation assignment (e.g.,
injections or exercise intervention
5. We recommend clearly indicating who was blinded and
describe the mechanisms by which this was accomplished.
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and
secondary outcomes
12b Methods for additional analyses, such as subgroup analyses
and adjusted analyses
2. We recommend that any stratiﬁcation and/or subset
analyses be speciﬁed prior to study deployment.
Results
Participant ﬂow
(a diagram is strongly
recommended)
13a For each group, the numbers of participants who were
randomly assigned, received intended treatment, and were
analyzed for the primary outcome
13b For each group, losses and exclusions after randomisation,
together with reasons
Recruitment 14a Dates deﬁning the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical
characteristics for each group
Numbers analyzed 16 For each group, number of participants (denominator)
included in each analysis and whether the analysis was by
original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each
group, and the estimated effect size and its precision (such
as 95% conﬁdence interval)
25. We recommend that clinical trial methodology and
results be reported in a format that allows for their inclusion
in pooled analyses.
17b For binary outcomes, presentation of both absolute and
relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including
subgroup analyses and adjusted analyses, distinguishing
pre-speciﬁed from exploratory
Harms 19 All important harms or unintended effects in each group
(for speciﬁc guidance see CONSORT for harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial
ﬁndings
Interpretation 22 Interpretation consistent with results, balancing beneﬁts
and harms, and considering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry 24. We recommend registering a clinical trial in the
appropriate registry prior to enrolling participants (e.g.,
Clinicaltrials.gov).
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of
drugs), role of funders
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maximum score ¼ 9).
An important foundation for clinical research is the public's
trust, which derives from transparency and the timely dissemina-
tion of research results. Sponsors and investigators share an ethical
obligation that encompasses prospective registration of clinicaltrials as well as the reporting of the consequences of this research.
Since the previous publication of these guidelines, numerous public
registries have been developed, and for clinical trials undertaken in
the United States federal regulations deﬁne which studies need to
be included and the extent of information to be publicly reported,
including summary study results94,95. Further information
regarding reporting studies and study results, as well as the
T.E. McAlindon et al. / Osteoarthritis and Cartilage 23 (2015) 747e760 757structure of these reports, can be found in the accompanying article
on key analytical considerations by Losina et al.
Summary
This document is an update to the 1996 recommendations on
the design and conduct of clinical trials in patients with OA. The
new recommendations focus on clinical trials, particularly phar-
maceutical and nutraceutical trials, among individuals with knee
OA and complement the other articles in this special issue that
address clinical trials in other study populations or speciﬁc aspects
of study design (e.g., statistical considerations, imaging). A strength
of these recommendations is that they were prepared by an in-
ternational panel that included clinicians, academic investigators,
and representatives from the pharmaceutical industry. Unfortu-
nately, no health agency representatives or patients were on the
working group as these groups may have offered unique insight
into the recommendations. These recommendations highlight key
areas that study teams and sponsors should consider when
designing, conducting, and reporting a clinical trial. We also
included a summary table that lists the CONSORT checklist with
these new recommendations (see Table II).
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